CompletedNCT03003156
50 Hz vs. 25 Hz Magnetic Seizure Therapy for Schizophrenia
This study has finished and is no longer accepting participants.
In ShanghaiSchizophreniaInterventional studyAges 18–55
Schizophrenia studies
Schizophrenia
Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.
CompletedNCT00018850
5HT3 Antagonism and Auditory Gating in Schizophrenia
This study has finished and is no longer accepting participants.
In DenverSchizophreniaMedication studyAges 18–55
CompletedNCT00265343
6-Month Extension study of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777)
Official study title
A Multicenter, Double-Blind, Flexible-Dose, 6-Month Extension Trial Comparing the Safety and Efficacy of Asenapine With Olanzapine in Subjects Who Completed the Protocol 25543 (NCT 00212836; P05817)
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18+
CompletedNCT00174265
6-Month Extension study of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month study (A7501014)(COMPLETED)(P05772)
Official study title
A Multicenter, Double-Blind, Flexible-Dose, 6-Month Extension Trial Comparing the Safety and Efficacy of Asenapine With Olanzapine in Subjects Who Completed Protocol A7501013
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18+
CompletedNCT00261430
A 2-year Study of people with Schizophrenia Who Are Treated With Long-acting Injectable Risperidone.
Official study title
Schizophrenia Treatment Acceptance Response Trial: a 20-week, Open-label, Multicenter, Randomized Study Comparing the Effect of the "GAIN Acceptance Approach Verses the "Approach-as-usual" in Supporting Patient Acceptance of Long-acting Risperidone (Risperdal� CONSTA�) in Adults With Schizophrenia
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaBehavioural studyAges 18–70
CompletedNCT01714713
EVP-6124 (Alpha-7 nAChR) for schizophrenia
What is this study about?
This study evaluated the safety of EVP-6124 for people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockSchizophreniaMedication studyAges 18–50
CompletedNCT00642369
A 4-week, Rater-blinded, Parallel Study to Evaluate Quetiapine in Improving Sleep Quality of Schizophrenia
Official study title
Study of Evaluating Quetiapine in Improving Sleep Quality of Schizophrenia
This study has finished and is no longer accepting participants.
In GuangzhouSchizophreniaMedication studyAges 18–65
CompletedNCT00645307
Safety study of Paliperidone ER in schizophrenia
Official study title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With an Open-Label Extension Evaluating Extended Release OROS® Paliperidone in the Prevention of Recurrence in Subjects With Schizophrenia - Open Label Phase
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18+
CompletedNCT00668837
A 52 Week Extension study Following the Efficacy and Safety Study R076477-SCH-305.
What is this study about?
This study evaluated the safety of Paliperidone for people with schizophrenia.
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18–65
CompletedNCT00650793
Safety study of Paliperidone ER in schizophrenia
Official study title
A Randomized, DB, PC and AC, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of 3 Fixed Dosages of Extended Release OROS� Paliperidone (6, 9, 12 mg/Day) and Olanzapine (10 mg/Day), With Open-Label Extension, in the Treatment of Subjects With Schizophrenia - Open Label Phase
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18+
CompletedNCT00645099
A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in people with Schizophrenia
Official study title
A Prospective Randomized Open-label 6-Month Head-To-Head Trial to Compare Metabolic Effects of Paliperidone ER and Olanzapine in Subjects With Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including Buenos AiresSchizophreniaMedication studyAges 18–65
CompletedNCT02880462
Sulforaphane add-on Effects for schizophrenia
Official study title
Phase 2 Study of the Effect of add-on Sulforaphane in Treatment of Schizophrenia
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaPlacebo comparisonAges 18–50
Registry coverage
We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.